1. Pharmacoepidemiology

2. Clinical Epidemiology and Evidence-based Medicine

1.Pharmacovigilance real world research. Bill and Melinda Gates Foundation,2021-2025

2.Strategies and Empirical Study on identifying and controlling time-related bias in pharmacoepidemiology. National Natural Science Foundation, 2020-2023

3.Development and optimization of multi-view and multi-modal irrational prescription detection model for clinical big data. National Natural Science Foundation, 2016-2019

4.Cohort consortium development for specific diseases of respiratory system. National key research and development program precision medicine. 2016-2020

5.Methodology study of the active surveillance of adverse drug reaction based on common data model in MDR-TB patient. National Natural Science Foundation, 2015-2018

6.The active surveillance of ADR of cardiovascular treatment. Beijing Science and Technology Project. 2015-2019 

7.Genome Epidemiology of anti-TB drug-induced liver injury in a Chinese cohort. National Natural Science Foundation, 2011-2014

8.The impact of genetic predisposition of drug-metabolizing enzymes on anti-tuberculosis drugs-induced liver injury: A nested case-control study.  National Natural Science Foundation, 2008-2010

9.Research of anti-tuberculosis drugs adverse reactions in National TB Control Program of China.  Global Fund China Tuberculosis Project, 2007-2009

10.Research of Drug Safety Evaluation Framework,  WHO HPSP project, 2008

1.Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J, Zhan S. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021 Jun;21(6):847-857.

2.Sun Y, Zhang L, Li N, Zhao H, Ma R, Fang T, Yang T, Xu G, Liu Z, Zhan S. No association between enterovirus 71 (EV71) vaccination and risk of febrile seizures: a population-based near real-time surveillance study. Expert Rev Vaccines. 2021 Dec 3:1-10.

3.Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J, Shen C, Feng Z, Zhan S. Progress of Active Surveillance for Vaccine Safety in China. China CDC Wkly. 2021 Jul 2;3(27):581-583.

4.Sun Y, Pei Z, Zhao H, Li L, Hu Y, Zhang L, Wang L, Yang Y, Huang T, Zhan S; China Cohort Consortium study group. Data Resource Profile: China Cohort Consortium (CCC). Int J Epidemiol. 2020 Oct 1;49(5):1436-1436m.

5.Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, Jia J, Liu L, Liu G, Wang J, Zhan S, Song C. Incidence of and trends in hip fracture among adults in urban China: A nationwide retrospective cohort study. PLoS Med. 2020 Aug 6;17(8):e1003180.

6.Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, Wang J, Zhan S, Gao P, Fan D. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020 May;91(5):520-525.

7.Xu Y, Wang T, Yang Z, Lin H, Shen P, Zhan S. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China. Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):635-643.

8.Yang Y, Zhou X, Gao S, Lin H, Xie Y, Feng Y, Huang K, Zhan S. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China[J]. Drug Saf, 2018 Jan;41(1):125-137.

9.Wu S, Xia Y, Lv X, Tang S, Yang Z, Zhang Y, Wang X, Hu D, Liu F, Yuan Y, Tu D, Sun F, Zhou L, Zhan S. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients[J]. J Gastroenterol Hepatol, 2015,30(3):540-545.

10.Chen R, Wang J, Zhang Y, Tang S, Zhan S. Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity[J]. Arch Toxicol, 2015,89(6):883-897.